FIELD: medicine, endocrinology, pharmacy.
SUBSTANCE: invention relates to new pharmaceutical compositions that comprise exendine or exendine agonist for treatment of diabetes mellitus, delaying in stomach evacuation or reducing food consumption, to their dosed formulations and methods for their administration. Compositions can be used in treatment of diabetes and states wherein reducing blood glucose level is useful, or retention and/or delaying in stomach evacuation, or inhibition in food consumption and these compositions comprise the parenteral liquid dosed formulation and dosed formulations that can be used in peroral, nasal, transbuccal, sublingual, intratracheal and pulmonary delivery of exendines and agonists of exendines.
EFFECT: valuable medicinal properties of compositions.
16 cl, 17 dwg, 204 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GLYCATED PEPTIDE GLP-1 | 2009 |
|
RU2543157C2 |
| METHOD FOR INHIBITING GLUCAGON | 2000 |
|
RU2247575C9 |
| GLP-1 ANALOGUE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND THEREOF APPLICATION | 2010 |
|
RU2565536C2 |
| SITE-SPECIFIC MONOPHYLATED ANALYGES OF EXCENDIN AND THE METHOD OF THEIR PRODUCTION | 2012 |
|
RU2625015C2 |
| METHOD OF PRODUCING GLYCOPROTEIN AND SCREENING METHOD | 2009 |
|
RU2520240C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS | 2018 |
|
RU2779314C2 |
| GLP-1 PEPTIDE HAVING ATTACHED OLIGOSACCHARIDE CHAIN | 2008 |
|
RU2539829C2 |
| METHODS FOR DELIVERY OF NEUROPROTECTIVE POLYPEPTIDE TO CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2790566C2 |
| ANALOG-AGONIST OF AMYLINE, ITS PHARMACEUTICALLY ACCEPTABLE SALTS, COMPOSITION EXHIBITING PROPERTIES OF AMYLINE AGONIST | 1992 |
|
RU2130463C1 |
